While transplant for patients 60 and older for high-risk hematologic malignancies has increased and observational data are promising, the risks and benefits of translant versus non-transplant remain largely unknown. We now have the tools and mechanisms to remove the blindfold!

The NHLBI should support the cooperative groups in conjunction with the BMT-CTN to establish a common framework for transplant trials in older... more »